Summary
In a multicentre study patients with liver metastases stratified to the histology of the primary tumour were investigated. A total of 102 patients with colorectal adenocarcinoma, non-small-cell lung cancer, pancreatic cancer, primary liver carcinoma and malignant melanoma were treated with the thioether lipid ilmofosine. The drug was administered orally as a tablet at a dosage of 150–300 mg/day (75 mg/tablet). The tolerability of ilmofosine was poor. There was a dose-limiting gastrointestinal toxicity with nausea, vomiting and loss of appetite (WHO grade II-IV) in 67% of patients. During the period of therapy (1–29 weeks, 8.5 weeks mean) no complete remission and no partial response were observed. We thus conclude that treatment with oral ilmofosine is not effective in patients with liver metastases due to various malignancies.
This is a preview of subscription content, log in via an institution to check access.
References
Berdel WE (1990) Ether lipids and derivatives as investigational anticancer drugs. Onkologie 13:245–250
Berdel WE, Andreesen R, Munder PG (1985). Synthetic alkylphospholipid analogs: a new class of antitumor agents. In: Kuo JF (ed) Phospholipids and cellular regulation. CRC Press Boca Raton Florida, USA 2:41–73
Bonjouhliem R, Phillips ML, Kuhler KM, Grindey GB, Poore GA, Schultz RW, Altom MG (1986) Studies on the antitumor activity of (2-alkoxyalkyl)- and (2-alkoxyalkanyl)-phosphocholines. J Med Chem 29:2472–2477
Drings P, Günther I, Khanavkar B (1990) Is stable disease a success of antineoplastic therapy? Alkyllysophospholipid-Edelfosinestudy results in non small cell lung cancer (NSCLC) patients. Cancer Res Clin Oncol 116 [Suppl I]:127
Fromm M, Berdel WE, Schick HD, Fink U, Pahlke O, Bicker U, Reichert A, Rastetter J (1987) Antineoplastic activity of the thioether lysophospholipid derivative BM 41.440 in vitro. Lipids 22:916–918
Heim ME, Kleeberg UR, Winkelmann M et al. (1991) Phase II trial of the thioether phospholipid analogue Ilmofosine in advanced malignant melanoma. Eur J Cancer 27 [Suppl 2]:158
Herrmann DBJ, Pahlke W, Munder PG, Bicker U (1988) Antineoplastic and antimetastatic activity of the thioether phospholipid ilmofosine (BM 41.440) in vivo. 79th Annual Meeting of the American Association of Cancer Research, May 25–28, New Orleans, USA
Khanavkar B, Ulbrich F, Gatzemeier U, Meyer-Schwickerath E, Lorenz J, Schreml WK, Brugger R, Schick HD, von Pawel J, Nordström R, Drings P (1989) Treatment of non-small cell lung cancer with the alkyllysophospholipid Edelfosine. Contrib Oncol 37:224–235
Munder PG, Modolell M, Bausert W, Oettgen HF, Westphal O (1981) Alkyllysophospholipids in cancer therapy. In: Hersh EM, Chirigos MA, Mastrangelo MD (eds) Augmenting agents in cancer therapy. Raven, New York, pp 441–457
Unger C, Eibl H, Breiser A, et al.. (1988) Phase I study with daily hexadecylphosophocholine in patients with malignant diseases. Onkologie 11:285–286
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Winkelmann, M., Ebeling, K., Strohmeyer, G. et al. Treatment results of the thioether lipid ilmofosine in patients with malignant tumours. J Cancer Res Clin Oncol 118, 405–407 (1992). https://doi.org/10.1007/BF01629421
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01629421